Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Understanding Tolebrutinib Fast Fact Series

• Tolebrutinib shifted microglia from a disease-associated to a homeostatic phenotype in a mouse model³

Effect on microglial gene expression in vitro³

At 48 weeks after crossing over to tolebrutinib, gene expression is altered in myeloid cells⁴

Tolebrutinib is an investigational agent and has not been approved for use by any regulatory authority.

Tolebrutinib is an investigational agent and has not been approved for use by any regulatory authority.

AIF1=allograft inflammatory factor 1; APOE=apolipoprotein E; BTK=Bruton’s tyrosine kinase; BTKi=BTK inhibitor; C1QC=complement C1Q C chain; CSF=cerebrospinal fluid; CSF1R=colony stimulating factor 1 receptor; HMC=human microglia clone; IC50=50% maximum drug inhibition; HLA=human leukocyte antigen; Ig=immunoglobulin; OPN=osteopontin; P2RY12=purinergic receptor P2Y12; P2RY13=purinergic receptor P2Y13; PwMS=people with MS; RGS1=regulator of G protein signalling 1; W=weeks.